Provided by Tiger Trade Technology Pte. Ltd.

Exicure, Inc.

3.66
+0.08352.33%
Volume:4.27K
Turnover:16.07K
Market Cap:23.35M
PE:-2.53
High:3.84
Open:3.83
Low:3.66
Close:3.58
52wk High:15.91
52wk Low:3.10
Shares:6.37M
Float Shares:2.33M
Volume Ratio:0.31
T/O Rate:0.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4479
EPS(LYR):-4.7478
ROE:-217.87%
ROA:-44.91%
PB:3.37
PE(LYR):-0.77

Loading ...

Exicure Inc - Appoints Gyuyeob Lee as Interim CFO - SEC Filing

THOMSON REUTERS
·
Feb 18

Exicure Inc - Andy Yoo Resigns as CEO and President of Exicure - SEC Filing

THOMSON REUTERS
·
Feb 18

Exicure Inc. Appoints Jung Soo Kim as CEO and Gyuyeob Lee as Interim CFO

Reuters
·
Feb 18

Exicure Inc. Appoints Three New Directors as CEO and CFO Resign

Reuters
·
Feb 11

Exicure kündigt erfolgreiche Phase-2-Studie mit Burixafor zur schnellen Stammzellmobilisierung bei Multiplem Myelom und Lymphom an

Reuters
·
Feb 05

Exicure Reports Phase 2 Success for Burixafor in Rapid Stem Cell Mobilization for Transplant Patients

Reuters
·
Feb 05

Exicure Achieves Milestone in Collaboration with GPCR Therapeutics

Reuters
·
Jan 23

Exicure to present data from burixafor Phase 2 trial at 2026 Tandem Meetings

TIPRANKS
·
Jan 21

Exicure Reports Positive Phase 2 Results for Burixafor in Multiple Myeloma Stem Cell Mobilization

Reuters
·
Jan 21

Exicure HiTron Inc. Reports Disposal of Exicure Inc. Common Shares

Reuters
·
Jan 21

Exicure HiTron Inc. Reports Disposal of Exicure Inc. Common Shares

Reuters
·
Jan 09

Crude Oil Down 1%; AutoZone Shares Dip After Q1 Results

Benzinga
·
Dec 10, 2025

Exicure Rally Fueled By Rapid Cell-Boosting Results In Blood Cancer Trial

Benzinga
·
Dec 10, 2025

Stocks to Watch: Alexander & Baldwin, Exicure, Mama's Creations

Dow Jones
·
Dec 09, 2025

Exicure Surges on Positive Data for Blood Cancer Treatment

Dow Jones
·
Dec 09, 2025

Exicure Reports Positive Phase 2 Results for Burixafor in Multiple Myeloma Stem Cell Mobilization

Reuters
·
Dec 09, 2025

Exicure Inc. Announces Early Redemption of $3.1 Million Convertible Bonds to Simplify Capital Structure

Reuters
·
Nov 18, 2025

Exicure Inc. Held Annual Shareholder Meeting

Reuters
·
Nov 11, 2025

Biotechnology company Exicure Q3 net loss widens, existing cash not sufficient to continue to fund operations

Reuters
·
Nov 08, 2025

Exicure Q3 EPS $(0.39) Up From $(0.57) YoY

Benzinga
·
Nov 08, 2025